Relmada Therapeutics (RLMD) Depreciation & Amortization (CF) (2013 - 2021)

Relmada Therapeutics (RLMD) has 9 years of Depreciation & Amortization (CF) data on file, last reported at -$1.3 million in Q3 2021.

• On a quarterly basis, Depreciation & Amortization (CF) rose 38.07% year-over-year to -$1.3 million in Q3 2021; TTM through Jun 2022 was -$1.3 million, a 38.01% increase from a year earlier, with the FY2021 full-year figure at $1258.0, down 66.47% from the prior year.
• Depreciation & Amortization (CF) for Q3 2021 stood at -$1.3 million, down from $452.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for RLMD reached as high as $23268.0 in Q1 2017 and fell as low as -$2.1 million in Q3 2020.
• Historically, Depreciation & Amortization (CF) has averaged -$185493.4 across 5 years, with a median of $926.0 in 2020.
• Across the five-year window, Depreciation & Amortization (CF) jumped 495.68% in 2019 and sank 64368.19% in 2020, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $582.0 in 2017, then slumped by 195.53% to -$556.0 in 2018, then soared by 495.68% to $2200.0 in 2019, then sank by 62.59% to $823.0 in 2020, then plunged by 157905.83% to -$1.3 million in 2021.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were -$1.3 million in Q3 2021, $452.0 in Q2 2021, and $806.0 in Q1 2021.